Profile of Hubei Xinankang Pharmaceutical Co., Ltd

Hubei Xinankang Pharmaceutical Co., Ltd., founded in July 2020, was restructured by Hubei Jiantang Group, Hubei Li Shizhen Modern Pharmaceutical Group and Hubei Chenkang Pharmaceutical. Hubei Xinankang Pharmaceutical has invested nearly 10 million yuan to build a new plant, increase production and inspection facilities and equipment, and restore the original supporting facilities of the production workshop. Through the investigation of the expert group of Hubei Provincial Drug Administration, obtained the first "two-in-one" drug production license in Hubei Province. At the same time of normal production and operation of the original factory, we invested 1 billion yuan to relocate and build a new large-scale comprehensive pharmaceutical factory in Huanggang. Relying on existing resources, the annual conservative output value will exceed 1 billion yuan.

Hubei Xinankang Pharmaceutical Co., Ltd. Production and business scope: Tablets, capsules, syrups, granules, paste and so on. The main products include: Chloroquine phosphate tablets, ursodeoxycholic acid tablets, furazolidone tablets, norfloxacin capsules, aminokahuangmin capsules, children's acetaminophen Huangnamin granules, Albendazole granules, worm breast milk cream, gynecological leucorrhizal cream, Chuanpei Qingfei syrup, pediatric cough syrup, lonicerae dew and other 6 dosage forms, a total of 42 national drug approval number products, after the establishment of the company, Seven production lines have been resumed, with an annual output of 100 million tablets, 10 million capsules, 10 million tons of granules, 5 million bottles of syrup, 10 million bottles of paste and 10 million bottles of honeysuckle dew. The extraction capacity of traditional Chinese medicine can reach 5000 tons/year.

Under the current epidemic situation, Hubei Xinankang Pharmaceutical will produce 50 million chloroquine phosphate tablets after resuming production. The output value exceeds 100 million yuan. At the same time, the investment in anti-infective drug research was increased, and the proportion of research investment in the operating revenue reached 3%. In the next two years, the company will gradually increase the investment in scientific research funds, which will account for about 4%-5% of sales revenue. A total of 40 million yuan to 50 million yuan is expected to be invested in scientific research to promote technological innovation and new product development. We will develop the company into a comprehensive pharmaceutical enterprise integrating new drug research and development and preparation production to achieve sustainable development of the company. According to the above development strategy and main business objectives, the company has formulated medium - and long-term development plans in research and development, production, marketing, human resources, fixed asset investment, etc., to ensure an average annual growth of more than 20% of the company's main business in the next five years. After normal operation, the annual sales revenue of the company will exceed 1 billion yuan, and grow into a large and medium-sized backbone enterprise in China's pharmaceutical industry.